Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:EQ NASDAQ:EVAX NASDAQ:LPTX NASDAQ:NERV On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEQEquillium$0.71+81.6%$0.37$0.27▼$1.50$13.97M1.15576,012 shs143.57 million shsEVAXEvaxion A/S$2.61-2.6%$2.58$1.20▼$17.75$3.76M0.13117,826 shs70,477 shsLPTXLeap Therapeutics$0.31-1.3%$0.35$0.22▼$4.79$12.85M-0.27331,448 shs213,029 shsNERVMinerva Neurosciences$1.93+2.9%$1.80$1.15▼$3.00$13.37M-0.3220,799 shs2,623 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEQEquillium+81.59%+76.31%+122.92%+69.05%-4.98%EVAXEvaxion A/S-2.61%-4.04%+5.67%+66.24%-81.75%LPTXLeap Therapeutics-1.29%-14.93%+6.25%-27.19%-85.70%NERVMinerva Neurosciences+0.79%-9.62%+12.90%+13.24%-35.19%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationEQEquillium1.814 of 5 stars3.24.00.00.00.61.70.0EVAXEvaxion A/S1.8229 of 5 stars3.52.00.00.01.61.70.0LPTXLeap Therapeutics1.9014 of 5 stars3.04.00.00.00.60.01.3NERVMinerva Neurosciences2.7486 of 5 stars3.03.00.04.60.00.01.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEQEquillium 2.33Hold$3.00322.54% UpsideEVAXEvaxion A/S 3.00Buy$10.00283.14% UpsideLPTXLeap Therapeutics 2.00Hold$3.381,002.94% UpsideNERVMinerva Neurosciences 2.00Hold$5.00159.74% UpsideCurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEQEquillium$41.10M0.62N/AN/A$0.54 per share1.31EVAXEvaxion A/S$3.34M1.09N/AN/A($1.18) per share-2.21LPTXLeap TherapeuticsN/AN/AN/AN/A$0.91 per shareN/ANERVMinerva NeurosciencesN/AN/A$0.22 per share8.95($3.67) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEQEquillium-$8.07M-$0.39N/AN/AN/A-19.62%-74.34%-46.75%8/6/2025 (Estimated)EVAXEvaxion A/S-$10.57M-$1.16N/AN/AN/A-316.03%-532.72%-78.32%8/13/2025 (Estimated)LPTXLeap Therapeutics-$67.56M-$1.70N/AN/AN/AN/A-162.15%-120.05%8/11/2025 (Estimated)NERVMinerva Neurosciences$1.44M$0.822.35N/AN/AN/A-20.68%15.73%8/5/2025 (Estimated)Latest EVAX, LPTX, NERV, and EQ EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025EQEquillium-$0.1850N/AN/AN/AN/AN/A8/13/2025Q2 2025EVAXEvaxion A/S-$0.50N/AN/AN/AN/AN/A8/11/2025Q2 2025LPTXLeap Therapeutics-$0.29N/AN/AN/AN/AN/A8/5/2025Q2 2025NERVMinerva Neurosciences-$0.95N/AN/AN/AN/AN/A5/27/2025Q1 2025EVAXEvaxion A/S-$0.65-$0.29+$0.36-$0.29$0.06 millionN/A5/13/2025Q1 2025LPTXLeap Therapeutics-$0.38-$0.37+$0.01-$0.37N/AN/A5/13/2025Q1 2025NERVMinerva Neurosciences-$1.07-$0.50+$0.57-$0.50N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEQEquilliumN/AN/AN/AN/AN/AEVAXEvaxion A/SN/AN/AN/AN/AN/ALPTXLeap TherapeuticsN/AN/AN/AN/AN/ANERVMinerva NeurosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEQEquilliumN/A2.702.70EVAXEvaxion A/SN/A2.012.01LPTXLeap TherapeuticsN/A2.412.41NERVMinerva NeurosciencesN/A9.219.21Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEQEquillium27.05%EVAXEvaxion A/S11.04%LPTXLeap Therapeutics30.46%NERVMinerva Neurosciences34.56%Insider OwnershipCompanyInsider OwnershipEQEquillium31.60%EVAXEvaxion A/S41.64%LPTXLeap Therapeutics7.50%NERVMinerva Neurosciences8.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEQEquillium4035.72 million24.43 millionNot OptionableEVAXEvaxion A/S601.40 million819,000No DataLPTXLeap Therapeutics4041.44 million38.33 millionOptionableNERVMinerva Neurosciences96.99 millionN/ANot OptionableEVAX, LPTX, NERV, and EQ HeadlinesRecent News About These CompaniesChandigarh: Minerva enter knockout stage of Gothia Cup 2025July 17, 2025 | msn.comMinerva CEO navigates 'nightmare' lab market to secure new HQ in WoburnJuly 16, 2025 | bizjournals.comMinerva University Named World's Most Innovative University for Fourth Consecutive YearJuly 15, 2025 | uk.finance.yahoo.comFree concert on Minerva’s Municipal Park StageJuly 14, 2025 | morningjournalnews.comMHelsinki Cup: Minerva Academy in Round-16 with thumping 7-0 winJuly 14, 2025 | msn.comMinerva narrowly fell short in final, but won hearts with historic Helsinki Cup campaignJuly 13, 2025 | english.newsnationtv.comEMinerva Academy FC: Defying Odds and Dazzling Europe in Helsinki Cup-2025July 13, 2025 | devdiscourse.comDHelsinki Cup: Minerva Academy in semi-finals, two Finland clubs eliminatedJuly 12, 2025 | english.newsnationtv.comEMinerva Neurosciences Inc. (NERV) Stock Price Today - WSJJuly 11, 2025 | wsj.comMinerva registers fourth win in Helsinki CupJuly 10, 2025 | msn.comHelsinki Cup: Minerva Academy logs twin victoriesJuly 10, 2025 | msn.comMinerva Academy FC's Triumph: An Unstoppable Force in Helsinki Cup 2025July 10, 2025 | devdiscourse.comDHelsinki Cup: Minerva registered its fourth win, creating history by winning the match 9-0July 10, 2025 | news.webindia123.comNMinerva High School Athletic Hall of Fame announces Class of 2025 membersJuly 10, 2025 | msn.comValCUN installs Minerva metal Additive Manufacturing machine at Johns Hopkins UniversityJuly 8, 2025 | metal-am.comMMinerva Avenue Charting Next Steps Following Sudden FireJuly 8, 2025 | msn.comFire destroys popular North Nashville nightclub Minerva AvenueJuly 6, 2025 | msn.comMinerva nights event to include music, food, gamesJune 27, 2025 | cantonrep.comCNordic Capital invests in CRO and CDMO Minerva ImagingJune 11, 2025 | pehub.comMinerva Neurosciences, Inc: Minerva Neurosciences Reports First Quarter 2025 Financial Results and Business UpdatesMay 14, 2025 | finanznachrichten.deNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Leaders Set to Gain From Rising Military SpendBy Chris Markoch | July 5, 2025View 3 Defense Leaders Set to Gain From Rising Military Spend3 Short Squeeze Candidates With Big Catalysts on the HorizonBy Dan Schmidt | July 25, 2025View 3 Short Squeeze Candidates With Big Catalysts on the HorizonHow a Government Loan Changes the Game for Plug PowerBy Jeffrey Neal Johnson | July 4, 2025View How a Government Loan Changes the Game for Plug PowerAmerica Wants Drone Dominance: Are These Stocks Ready to Soar?By Chris Markoch | July 20, 2025View America Wants Drone Dominance: Are These Stocks Ready to Soar?Will Hims & Hers Fall Along With Novo Nordisk?By Gabriel Osorio-Mazilli | August 1, 2025View Will Hims & Hers Fall Along With Novo Nordisk?EVAX, LPTX, NERV, and EQ Company DescriptionsEquillium NASDAQ:EQ$0.71 +0.32 (+81.59%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$0.57 -0.14 (-19.01%) As of 08/1/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis. It also develops EQ101 completed phase 1/2 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ302 to treat gastrointestinal indications. In addition, it serves dermatology, gastroenterology, rheumatology, hematology, transplant science, oncology, and pulmonology area. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.Evaxion A/S NASDAQ:EVAX$2.61 -0.07 (-2.61%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$2.60 0.00 (-0.19%) As of 08/1/2025 05:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers. Its programs also include some vaccines that are in pre-clinical stage, which includes EVX-B1 for the prevention of S. aureus-induced skin and soft tissue infections in patients undergoing elective abdominal hernia surgery; EVX-B2 to target diseases caused by N. gonorrhoeae; EVX-B3 for eliciting strong humoral antibody and cellular immune response to the bacterial pathogen; and EVX-V1, viral vaccine product candidate for targeting Cytomegalovirus. Evaxion Biotech A/S was incorporated in 2008 and is based in Horsholm, Denmark.Leap Therapeutics NASDAQ:LPTX$0.31 0.00 (-1.29%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$0.31 0.00 (0.00%) As of 08/1/2025 06:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501. Leap Therapeutics, Inc. has an option and license agreement with NovaRock, Adimab, and BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.Minerva Neurosciences NASDAQ:NERV$1.92 +0.06 (+2.94%) Closing price 08/1/2025 03:45 PM EasternExtended Trading$1.92 0.00 (0.00%) As of 08/1/2025 04:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/28 - 08/01 Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale AbbVie Stock Eyes Breakout as Pipeline and Profits Grow Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
